JP2023526348A5 - - Google Patents

Info

Publication number
JP2023526348A5
JP2023526348A5 JP2022570127A JP2022570127A JP2023526348A5 JP 2023526348 A5 JP2023526348 A5 JP 2023526348A5 JP 2022570127 A JP2022570127 A JP 2022570127A JP 2022570127 A JP2022570127 A JP 2022570127A JP 2023526348 A5 JP2023526348 A5 JP 2023526348A5
Authority
JP
Japan
Prior art keywords
viral vector
viral
cell line
producing
accessory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022570127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526348A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/032479 external-priority patent/WO2021231884A1/en
Publication of JP2023526348A publication Critical patent/JP2023526348A/ja
Publication of JP2023526348A5 publication Critical patent/JP2023526348A5/ja
Pending legal-status Critical Current

Links

JP2022570127A 2020-05-15 2021-05-14 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 Pending JP2023526348A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063025812P 2020-05-15 2020-05-15
US63/025,812 2020-05-15
PCT/US2021/032479 WO2021231884A1 (en) 2020-05-15 2021-05-14 Compositions and methods for producing stable viral vector producer cells for cell and gene therapy

Publications (2)

Publication Number Publication Date
JP2023526348A JP2023526348A (ja) 2023-06-21
JP2023526348A5 true JP2023526348A5 (https=) 2024-05-22

Family

ID=76306023

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022570127A Pending JP2023526348A (ja) 2020-05-15 2021-05-14 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法

Country Status (6)

Country Link
US (1) US20220154215A1 (https=)
EP (1) EP4150097A1 (https=)
JP (1) JP2023526348A (https=)
KR (1) KR20230017799A (https=)
CA (1) CA3183599A1 (https=)
WO (1) WO2021231884A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3965829A4 (en) 2019-05-06 2023-05-24 Malcolm, Thomas ADAPTED HYPOIMMUNE NANOVESICULAR DELIVERY SYSTEM FOR CANCER TUMORS
US12054738B2 (en) 2020-07-30 2024-08-06 Shape Therapeutics Inc. Stable cell lines for inducible production of rAAV virions
TW202323529A (zh) 2021-10-18 2023-06-16 美商再生元醫藥公司 包括腺病毒相關病毒聚核苷酸的真核細胞
WO2023230230A1 (en) * 2022-05-25 2023-11-30 Malcolm Thomas Tailored hypoimmunogenic biomimetic nanovesicle delivery system for viral infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981276A (en) 1990-06-20 1999-11-09 Dana-Farber Cancer Institute Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof
CA2344208A1 (en) * 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US20140315294A1 (en) * 2011-11-24 2014-10-23 Genethon Scalable lentiviral vector production system compatible with industrial pharmaceutical applications
PL3294893T3 (pl) * 2015-05-13 2024-04-29 Csl Behring Gene Therapy, Inc. Bioprodukcja wektorów lentiwirusowych
JP7098521B2 (ja) * 2015-11-24 2022-07-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド レトロウイルス産生のための安定な細胞株
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
JP7470119B2 (ja) * 2018-08-24 2024-04-17 シーエスエル ベーリング ジーン セラピー インコーポレイテッド 無血清培地におけるベクター産生

Similar Documents

Publication Publication Date Title
JP2023526348A5 (https=)
RU2752498C2 (ru) Стабильные клеточные линии для продуцирования ретровирусов
Ni et al. Generation of a packaging cell line for prolonged large‐scale production of high‐titer HIV‐1‐based lentiviral vector
AU2022218478B2 (en) Bio-production of lentiviral vectors
KR20200056429A (ko) 레트로바이러스 벡터
KR20130101527A (ko) 렌티바이러스 벡터의 안정한 제조
Kiem et al. Foamy combinatorial anti-HIV vectors with MGMTP140K potently inhibit HIV-1 and SHIV replication and mediate selection in vivo
Adamson et al. Approaches to maximize sgRNA-barcode coupling in Perturb-seq screens
JP2023552663A (ja) 安定したレンチウイルスパッケージング細胞株およびその作成方法
JP6878620B2 (ja) レトロウイルス産生のための安定な細胞株
US20240167055A1 (en) Compositions and methods for producing and characterizing viral vector producer cells for cell and gene therapy
AU2021206846B2 (en) Lentivirus packaging system, method for improving lentivirus production in a host cell, and method for treating cancer
Santhosh et al. A lentiviral vector with novel multiple cloning sites: stable transgene expression in vitro and in vivo
Kim et al. Development of a safe and rapid neutralization assay using murine leukemia virus pseudotyped with HIV type 1 envelope glycoprotein lacking the cytoplasmic domain
US9840720B2 (en) Materials and methods relating to packaging cell lines
Jespersen et al. Expression of heterologous genes from an IRES translational cassette in replication competent murine leukemia virus vectors
US20110008894A1 (en) Lyophilized plasmid/dna transfection reagent carrier complex
Reil et al. CD4 expressing human 293 cells as a tool for studies in HIV-1 replication: the efficiency of translational frameshifting is not altered by HIV-1 infection
CN113832191B (zh) 慢病毒载体、系统及其应用
KR20240024807A (ko) 렌티바이러스 벡터
JP4482639B2 (ja) レンチウイルスベクターに対する効率的なパッケージング細胞を産生するための選択システム
WO2005123930A1 (en) Lentiviral vector
Miklík et al. Long Terminal Repeats of Gammaretroviruses Retain Stable Expression After Integration Retargeting or Knock-In into the Restrictive Chromatin of Lamina-Associated Domains
KR102704463B1 (ko) 렌티바이러스를 이용한 차세대 시퀀싱 기반 재조합 단백질 발현을 위한 세포 내 고발현 영역 탐색 방법 및 고발현 영역 정보
LLC Development and Optimization of a High Titer Recombinant Lentivirus System